Table I.
Clinical characteristics and laboratory observations.
| All patients (n=103) | HF (n=20) | No HF (n=83) | P-value | |
|---|---|---|---|---|
| Male, n (%) | 88 (85.4) | 14 (70.0) | 74 (89.2) | 0.029 |
| Age, years | 57.6±12.1 | 64.9±11.7 | 55.9±11.6 | 0.002 |
| Hypertension, n (%) | 49 (47.6) | 12 (60.0) | 37 (44.6) | 0.319 |
| Diabetes mellitus, n (%) | 24 (23.3) | 5 (25.0) | 19 (22.9) | 0.842 |
| Hyperlipidemia, n (%) | 46 (44.7) | 8 (40.0) | 38 (45.8) | 0.803 |
| Current smokers, n (%) | 80 (77.7) | 13 (65.0) | 67 (80.7) | 0.103 |
| Systolic blood pressure, mmHg | 137.4±29.9 | 136.0±38.7 | 137.8±27.6 | 0.819 |
| Heart rate, beats/minute | 74.4±14.9 | 74.4±17.4 | 74.4±14.3 | 1.000 |
| Time from symptom onset to reperfusion, min | 240 (193–367) | 285 (220–400) | 230 (180–365) | 0.168 |
| Culprit vessel | ||||
| LAD, n (%) | 57 (55.3) | 12 (60.0) | 45 (54.2) | 0.803 |
| Other vessels, n (%) | 46 (44.7) | 8 (40.0) | 38 (45.8) | |
| LVEF, % | 52.2±7.8 | 48.1±7.3 | 53.3±7.6 | 0.007 |
| NT-proBNP, pg/ml | 1,027 (450–1,941) | 3,369 (1,112–4,778) | 829 (375–1,379) | <0.001 |
| Peak cTnT, ng/ml | 3.8 (2.0–6.8) | 6.9 (3.3–10) | 3.1 (2.0–5.3) | 0.002 |
| Hs-CRP, mg/l | 6.3 (2.5–15.0) | 7.0 (4.7–31.2) | 6.2 (2.1–13.2) | 0.088 |
| WBC count, 109/l | 10.6±3.5 | 10.2±3.5 | 10.7±3.5 | 0.586 |
| Hb, g/L | 147.3±16.5 | 141.8±21.3 | 148.7±14.9 | 0.092 |
| Serum creatinine, umol/l | 75.8±13.7 | 76.6±11.6 | 75.6±14.2 | 0.782 |
| Ang-1, pg/ml | 19,885.0±1,891.3 | 19,575.5±2,425.5 | 19,959.6±1,748.5 | 0.418 |
| Ang-2, pg/ml | 2,121.9±122.1 | 2,203.1±122.0 | 2,102.3±114.4 | 0.001 |
| Ang-2/Ang-1, 10−2 | 10.8±1.2 | 11.4±1.6 | 10.6±1.1 | 0.007 |
Data are presented as mean ± SD, median (inter-quartile range) or percentages. Ang, angiopoietin; Ang-2/Ang-1, Ang-2 to Ang-1 ratio; Hb, hemoglobin; HF, heart failure; Hs-CRP, high-sensitivity-CRP; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; cTnT, cardiac troponin T; WBC, white blood cell.